Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources
Phase 0/I/II Cancer Prevention Clinical Trials Program
(Consortia for Early Phase Prevention Trials)

Publications

  • Berg AK, Mandrekar SJ, Ziegler KL, Carlson EC, Szabo E, Ames MM, Boring D, Limburg PJ, Reid JM; Cancer Prevention Network. Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects. J Clin Pharmacol. 2013 Apr;53(4):403-12. Epub 2013 Feb 22.
    [ PubMed Abstract ]
  • Limburg PJ, Mandrekar SJ, Aubry MC, Ziegler KL, Zhang J, Yi JE, Henry M, Tazelaar HD, Lam S, McWilliams A, Midthun DE, Edell ES, Rickman OB, Mazzone P, Tockman M, Beamis JF, Lamb C, Simoff M, Loprinzi C, Szabo E, Jett J; Cancer Prevention Network. Randomized phase II trial of sulindac for lung cancer chemoprevention. Lung Cancer. 2013 Mar;79(3):254-61. Epub 2012 Dec 20.
    [ PubMed Abstract ]
  • Lu KH, Loose DS, Yates MS, Nogueras-Gonzalez GM, Munsell MF, Chen LM, Lynch H, Cornelison T, Boyd-Rogers S, Rubin M, Daniels MS, Conrad P, Milbourne A, Gershenson DM, Broaddus RR. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res (Phila). 2013 Aug;6(8):774-81. Epub 2013 May 2.
    [ PubMed Abstract ]
  • Mohebati A, Milne GL, Zhou XK, Duffield-Lillico AJ, Boyle JO, Knutson A, Bosworth BP, Kingsley PJ, Marnett LJ, Brown PH, Akpa EG, Szabo E, Dannenberg AJ. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers. Cancer Prev Res (Phila). 2013 Jul;6(7):646-55. Epub 2013 May 16.
    [ PubMed Abstract ]
  • Wong SJ, Campbell B, Massey B, Lynch DP, Cohen EE, Blair E, Selle R, Shklovskaya J, Jovanovic BD, Skripkauskas S, Dew A, Kulesza P, Parimi V, Bergan RC, Szabo E. A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia. Oral Oncol. 2013 Sep;49(9):970-6. Epub 2013 Jul 8.
    [ PubMed Abstract ]
  • Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res 2012 Sept 5: 1144-1154.
    [ PubMed Abstract ]
  • Curiel-Lewandrowski C, Swetter SM, Einspahr JG, Hsu CH, Nagle R, Sagerman P, Tangrea J, Parnes H, Alberts DS, Chow HH. Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: Evaluation of potential chemopreventive activity. Cancer 2012 Dec 1;118(23):5848-56. Epub 2012 May 17
    [ PubMed Abstract ]
  • Falk GW, Buttar NS, Foster NR, Ziegler KL, Demars CJ, Romero Y, Marcon NE, Schnell T, Corley DA, Sharma P, Cruz-Correa MR, Hur C, Fleischer DE, Chak A, Devault KR, Weinberg DS, Della'zanna G, Richmond E, Smyrk TC, Mandrekar SJ, Limburg PJ. A Combination of Esomeprazole and Aspirin Reduces Tissue Concentrations of Prostaglandin E(2) in Patients With Barrett's Esophagus. Gastroenterology 2012 Oct;143(4):917-26. Epub 2012 Jul 11
    [ PubMed Abstract ]
  • Khan SA, Chatterton RT, Michel N, Bryk M, Lee O, Ivancic D, Heinz R, Zalles CM, Helenowski IB, Jovanovic BD, Franke AA, Bosland MC, Wang J, Hansen NM, Bethke KP, Dew A, Coomes M, Bergan RC. Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial. Cancer Prev Res 2012 Feb;5(2):309-19.
    [ PubMed Abstract ]
  • Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, Bailey H. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res 2012 Apr;5(4):621-30. Epub 2012 Jan 31.
    [ PubMed Abstract ]
  • Mohebati A, Knutson A, Zhou XK, Smith JJ, Brown PH, Dannenberg AJ, Szabo E. A Web-Based Screening and Accrual Strategy for a Cancer Prevention Clinical Trial in Healthy Smokers. Contemp Clin Trials 2012 Sept; 33:942-948.
  • Nguyen MM, Ahmann FR, Nagle RB, Hsu CH, Tangrea JA, Parnes HL, Sokoloff MH, Gretzer MB, Chow HH. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev Res 2012 Feb;5(2):290-8. Epub 2011 Nov 1.
    [ PubMed Abstract ]
  • Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL, Jr., Brenner DE. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res 2011 Mar;4(3):354-64.
    [ PubMed Abstract ]
  • Limburg PJ, Mahoney MR, Ziegler KL, Sontag SJ, Schoen RE, Benya R, Lawson MJ, Weinberg DS, Stoffel E, Chiorean M, Heigh R, Levine J, Della'Zanna G, Rodriguez L, Richmond E, Gostout C, Mandrekar SJ, Smyrk TC. Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention. Cancer Prev Res 2011 Feb;4(2):259-69. Epub 2011 Jan 5
    [ PubMed Abstract ]
  • Lipkin S, Lee J, Imagawa D, Hewitt SM, Tucker C, Zell JA, Wong V, Garcia A, Gonzalez R, Della Zanna G, Richmond E, Rodriguez LM, Bigg M, Schnoll-Sussmans F, Meyskens F. Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms. Cancer Prev Res 2011 Apr;4(4):512-3.
    [ PubMed Abstract ]
  • Marshall JR, Ip C, Romano K, Fetterly G, Fakih M, Jovanovic B, Perloff M, Crowell J, Davis W, French-Christy R, Dew A, Coomes M, Bergan R. Methyl selenocysteine: single-dose pharmacokinetics in men. Cancer Prev Res 2011 Nov;4(11):1938-44. Epub 2011 Aug 16
    [ PubMed Abstract ]
  • Reid JM, Walden CA, Qin R, Ziegler KL, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Bauer BA, Mandrekar SJ, Ames MM, Limburg PJ. Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res 2011 Mar;4(3):347-53.
    [ PubMed Abstract ]
  • Veronesi G, Szabo E, Decensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Ferretti S, Pelosi G, Lazzeroni M, Serrano D, Lippman SM, Spaggiari L, Nardi-Pantoli A, Harari S, Varricchio C, Bonanni B. Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res 2011 Jan;4(1):34-42. Epub 2010 Dec 16
    [ PubMed Abstract ]
  • Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res . 2010 Sep;3(9):1168-75. Epub 2010 Aug 17
    [ PubMed Abstract ]
  • Kolesar JM, Hoel R, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Krontiras H, Brouillette W, Muccio D, Kim K, Grubbs CJ, Bailey HE. A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers. Cancer Prev Res 2010 Dec;3(12):1565-70.
    [ PubMed Abstract ]
  • Lazzeroni M, Guerrieri-Gonzaga A, Serrano D, Varricchio MC, Veronesi G, Radice D, Feroce I, Nardi-Pantoli A, Lippman SM, Szabo E, Bonnanni B.  Budesonide versus Placebo in High-risk Population with Screen-detected Lung Nodules:  Rationale, Design and Methodology.  Contemp Clin Trials 31:612, 2010.
  • Thompson PA, Hsu CH, Green S, Stopeck AT, Johnson K, Alberts DS, Chow HH. Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial. Cancer Prev Res 2010 Jan;3(1):101-7.
    [ PubMed Abstract ]
  • No publications at this time.
  • Reid JM, Mandrekar SJ, Carlson EC, Harmsen WS, Green EM, McGovern RM, Szabo E, Ames MM, Boring D, Limburg PJ. Comparative bioavailability of sulindac in capsule and tablet formulations. Cancer Epidemiol Biomarkers Prev 2008 Mar;17(3):674-9 .
    [ PubMed Abstract ]

Back to top